Cargando…

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy

PURPOSE: Few data are available concerning the clinical outcome of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in terms of the duration of androgen deprivation therapy (ADT) before diagnosis of CRPC. We investigated the clinical efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ki Bom, Jo, Jung Ki, Ahn, Soyeon, Lee, Sangchul, Jeong, Seong Jin, Hong, Sung Kyu, Byun, Seok-Soo, Lee, Sang Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534432/
https://www.ncbi.nlm.nih.gov/pubmed/26279827
http://dx.doi.org/10.4111/kju.2015.56.8.580
_version_ 1782385453553418240
author Kim, Ki Bom
Jo, Jung Ki
Ahn, Soyeon
Lee, Sangchul
Jeong, Seong Jin
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
author_facet Kim, Ki Bom
Jo, Jung Ki
Ahn, Soyeon
Lee, Sangchul
Jeong, Seong Jin
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
author_sort Kim, Ki Bom
collection PubMed
description PURPOSE: Few data are available concerning the clinical outcome of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in terms of the duration of androgen deprivation therapy (ADT) before diagnosis of CRPC. We investigated the clinical efficacy of abiraterone acetate according to the duration of ADT. MATERIALS AND METHODS: We reviewed the medical records of 20 patients with mCRPC who received abiraterone acetate after failure of docetaxel chemotherapy from May 2012 to March 2014 at Seoul National University Bundang Hospital. Clinical factors including prostate-specific antigen (PSA) nadir level, time to PSA nadir, PSA doubling time, PSA response, and modes of progression (PSA, radiologic, clinical) were analyzed. Disease progression was classified according to the Prostate Cancer Working Group 2 criteria. RESULTS: The mean age and PSA value of the entire cohort were 76.0±7.2 years and 158.8±237.9 ng/mL, respectively. The median follow-up duration was 13.4±6.7 months. There were no statistically significant differences in clinical characteristics between patients who received abiraterone acetate with ADT duration<35 months and those who received abiraterone acetate with ADT duration≥35 months. There were also no significant differences in terms of PSA progression-free survival, radiologic progression-free survival, and clinical progression-free survival between patients with ADT duration<35 months and those with ADT duration ≥35 months. CONCLUSIONS: Although this was a retrospective study with a small sample size, we did not observe any statistically significant differences in the clinical response to abiraterone acetate between mCRPC patients with long ADT duration and those with short ADT duration in terms of disease progression-free survival.
format Online
Article
Text
id pubmed-4534432
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Korean Urological Association
record_format MEDLINE/PubMed
spelling pubmed-45344322015-08-16 Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy Kim, Ki Bom Jo, Jung Ki Ahn, Soyeon Lee, Sangchul Jeong, Seong Jin Hong, Sung Kyu Byun, Seok-Soo Lee, Sang Eun Korean J Urol Original Article PURPOSE: Few data are available concerning the clinical outcome of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in terms of the duration of androgen deprivation therapy (ADT) before diagnosis of CRPC. We investigated the clinical efficacy of abiraterone acetate according to the duration of ADT. MATERIALS AND METHODS: We reviewed the medical records of 20 patients with mCRPC who received abiraterone acetate after failure of docetaxel chemotherapy from May 2012 to March 2014 at Seoul National University Bundang Hospital. Clinical factors including prostate-specific antigen (PSA) nadir level, time to PSA nadir, PSA doubling time, PSA response, and modes of progression (PSA, radiologic, clinical) were analyzed. Disease progression was classified according to the Prostate Cancer Working Group 2 criteria. RESULTS: The mean age and PSA value of the entire cohort were 76.0±7.2 years and 158.8±237.9 ng/mL, respectively. The median follow-up duration was 13.4±6.7 months. There were no statistically significant differences in clinical characteristics between patients who received abiraterone acetate with ADT duration<35 months and those who received abiraterone acetate with ADT duration≥35 months. There were also no significant differences in terms of PSA progression-free survival, radiologic progression-free survival, and clinical progression-free survival between patients with ADT duration<35 months and those with ADT duration ≥35 months. CONCLUSIONS: Although this was a retrospective study with a small sample size, we did not observe any statistically significant differences in the clinical response to abiraterone acetate between mCRPC patients with long ADT duration and those with short ADT duration in terms of disease progression-free survival. The Korean Urological Association 2015-08 2015-08-06 /pmc/articles/PMC4534432/ /pubmed/26279827 http://dx.doi.org/10.4111/kju.2015.56.8.580 Text en © The Korean Urological Association, 2015 http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Ki Bom
Jo, Jung Ki
Ahn, Soyeon
Lee, Sangchul
Jeong, Seong Jin
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
title Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
title_full Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
title_fullStr Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
title_full_unstemmed Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
title_short Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
title_sort clinical effect of abiraterone acetate in korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534432/
https://www.ncbi.nlm.nih.gov/pubmed/26279827
http://dx.doi.org/10.4111/kju.2015.56.8.580
work_keys_str_mv AT kimkibom clinicaleffectofabirateroneacetateinkoreanpatientswithmetastaticcastrationresistantprostatecanceraccordingtodurationofandrogendeprivationtherapy
AT jojungki clinicaleffectofabirateroneacetateinkoreanpatientswithmetastaticcastrationresistantprostatecanceraccordingtodurationofandrogendeprivationtherapy
AT ahnsoyeon clinicaleffectofabirateroneacetateinkoreanpatientswithmetastaticcastrationresistantprostatecanceraccordingtodurationofandrogendeprivationtherapy
AT leesangchul clinicaleffectofabirateroneacetateinkoreanpatientswithmetastaticcastrationresistantprostatecanceraccordingtodurationofandrogendeprivationtherapy
AT jeongseongjin clinicaleffectofabirateroneacetateinkoreanpatientswithmetastaticcastrationresistantprostatecanceraccordingtodurationofandrogendeprivationtherapy
AT hongsungkyu clinicaleffectofabirateroneacetateinkoreanpatientswithmetastaticcastrationresistantprostatecanceraccordingtodurationofandrogendeprivationtherapy
AT byunseoksoo clinicaleffectofabirateroneacetateinkoreanpatientswithmetastaticcastrationresistantprostatecanceraccordingtodurationofandrogendeprivationtherapy
AT leesangeun clinicaleffectofabirateroneacetateinkoreanpatientswithmetastaticcastrationresistantprostatecanceraccordingtodurationofandrogendeprivationtherapy